QGEN Profile
QIAGEN N.V., headquartered in Venlo, the Netherlands, is a global leader in providing comprehensive sample to insight solutions that revolutionize biological materials into molecular insights across the world. Established in 1986, the company offers a wide array of technologies and consumables tailored for primary and secondary sample processing, encompassing nucleic acid stabilization, purification kits, and automated processing solutions for genotyping, gene expression analysis, and microbial testing. QIAGEN leverages advanced silica membranes and magnetic bead technologies to enhance the efficiency and accuracy of molecular diagnostics.
The company's product portfolio includes assays for a diverse range of applications, from TB testing and post-transplant monitoring to prenatal testing, sexually transmitted diseases, and HPV detection. QIAGEN also specializes in genomic variant analysis, including mutations, insertions, deletions, and fusions, alongside advanced instruments for one-step molecular analysis and integrated PCR testing.
QIAGEN's offerings extend to PCR consumables such as quantitative PCR and reverse transcription kits, essential for gene expression analysis, genotyping, and gene regulation studies. Additionally, the company provides human ID and forensics assay consumables, including STR assays for human identification and assays addressing food contamination concerns. Its digital PCR solutions and OEM consumables further underscore its commitment to advancing molecular testing technologies.
Catering to molecular diagnostics, academia, pharmaceutical, and applied testing sectors, QIAGEN collaborates through strategic alliances with Sysmex Corporation and OncXerna Therapeutics, and maintains partnerships with organizations like Mirati. With a global presence and a dedication to innovation, QIAGEN N.V. continues to drive progress in molecular biology and personalized healthcare solutions, setting benchmarks in the field of genomic research and laboratory diagnostics.
|